Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation

Somy Yoon and Gwang Hyeon Eom*
Department of Pharmacology, Chonnam National University Medical School, Hwasun, Korea

Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.

Key Words: CAR T cell; Neoplasms; T-Lymphocytes; Combined Modality Therapy; Ligands

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Our body is exposed to various stimuli from the external environment. Due to direct exposure to the environment, and with a large surface area, the skin and gastrointestinal tract encounter various pathogens and function as the primary barrier to protect the host.1 If a pathogen penetrates this barrier, the special defense system of its host, i.e., the immune system, is activated.2 As the defense employed to protect the host from external invaders, the immune system is often compared to an army. The immune system comprises humoral immunity and cell-mediated immunity.3 B cell-based humoral immune cells produce a variety of antibodies to neutralize extracellular pathogens. Cytotoxic lymphocytes, cytotoxic T cells, and natural killer cells contribute to cell-mediated immunity. Cytotoxic lymphocytes distinguish between normal cells and abnormal cells, such as pathogen-infected host cells, and trigger the death signal in those infected cells.7 Besides fighting infection, immune cells induce the death of ‘strange’ host cells and maintain host homeostasis. Various ligands of normal host cells correspond to receptors on cytotoxic cells; thus, ligand-receptor binding suppresses the activation of the cytotoxic cells.4 Cytotoxic lymphocytes recognize selfness through their own receptor activity. In the case of different surface antigens being presented, cytotoxic cells are activated, this being the main contribution to the cytotoxic clearance of the infected cell or the non-self cell (i.e., the transplanted organ).3,4 Because cell mediated immune function can directly induce cell death, the cytotoxic clearance mechanism is tightly regulated by multiple steps.5 Paradoxically, this self-sorting immune check system allows malignant cancer cells to evade the cell-mediated immune reaction.6 Recently, engineered T cells that can specifically target cancer antigens, chimeric antigen receptor T cells (CAR T cell), have emerged as novel immunotherapeutic modality.
the most frequently observed mutation in the development of colorectal cancer from preneoplastic lesions.\textsuperscript{8} Cytotoxic lymphocytes also recognize ‘strange’ cells that develop as a result of somatic mutations; therefore, the tumor cell can be cleared under the surveillance of the immune system.\textsuperscript{9} However, an accumulation of somatic mutations can disguise their identity through the loss of antigenicity.\textsuperscript{10} In this way, cytotoxic leukocytes can fail to recognize an unhealthy cell because it shows normal surface antigens. Besides the passive mechanism of loss of antigenicity, cancer cells can actively incapacitate the immune system. Cancer cells generate immune modulating factors on their cell membrane to evade cytotoxic T cell recognition.\textsuperscript{10} PD-L1 binds to the PD-1 receptor\textsuperscript{11} and the B7 factor\textsuperscript{12} specifically binds to CTLA-4 on a cytotoxic T cell. Ligand binding of PD-1 or CTLA-4 inactivates cytotoxic T cells, which results in immune escape.\textsuperscript{10} Furthermore, cancer cells indirectly suppress the cell-mediated immune system. Cancer cells actively secrete immunosuppressive molecules such as those from the galectin family,\textsuperscript{13}\textsuperscript{15} the CXCL family,\textsuperscript{14} or inhibitory interleukins (e.g., IL-10).\textsuperscript{10} These are released from cancer cells and activate various immune regulatory cells such as myeloid-derived suppressor cells, regulatory T cells, tumor-associated macrophages, or tumor-associated neutrophils. These cells neutralize the cytotoxic immune response and thereby permit cancer cell survival and expansion. In short, cancer cells actively generate immune escape tools to survive in the zones of massive inflammation.\textsuperscript{6}

CHIMERIC ANTIGEN RECEPTOR T CELL

Although abundant immune cells are accumulated in the cancerous region, the immune system deteriorates.\textsuperscript{6} Cancer cells interfere with the activation of cytotoxic T cells. Cytotoxic T cell activation requires multiple fastidious steps to avoid abnormal activation, this tight regulation granting an adverse immune evasion opportunity to the cancer cell.\textsuperscript{16} Even if only one activation molecule is missing from the signaling pathway, the T cell will not be activated. Cancer cells can easily incapacitate the host immune system simply through inhibition of one ligand of the T cell.\textsuperscript{16} Hence, many researchers have trialed methods to recover the cell-mediated immune response. The goal of these engineered cells is to specifically target cancer cells and overcome the immunosuppressive microenvironment created by them.\textsuperscript{17-19} To specifically target cells of malignant cancer, antibodies that target cancer cells are utilized. For the simplification of therapy, diverse but essential factors for T cell activation are combined into a single receptor. Cancer-specific recognition parts are fused to form the external part of the receptor. This T cell, which carries a chimeric antigen receptor on its cell membrane, is known as the chimeric antigen receptor (CAR) T cell.\textsuperscript{19} Fig. 1 demonstrates CAR T cell generation and elucidates its structure. CAR T cell therapy shares clinical features with monoclonal antibody therapy.\textsuperscript{20} Extremely specific ligands for antigen recognition are mandatory for CAR T cell generation, which is mostly adopted from the antigen binding motif of monoclonal antibodies. Monoclonal antibody therapy is an emerging strategy to target not only malignant cancer but also chronic refractory disease.\textsuperscript{21} The primary characteristic of a monoclonal antibody is that it is a macromolecule and its therapeutic potential largely depends on the flow of the bloodstream, which means a monoclonal antibody is hardly ever delivered to hypoxic areas.\textsuperscript{22} Furthermore, the monoclonal antibody itself could possibly trigger an immune response in the host, resulting in therapeutic failure of the neutralizing antibody.\textsuperscript{23} In contrast, as a CAR T cell is a “cell” active mobility and target recognition is easily achieved.\textsuperscript{24} The cells used in CAR T cell therapy are originally obtained from the host, then modified to acquire chimeric antigen receptors. Therefore, secondary immune activation is rarely induced.\textsuperscript{25}

To transduce the chimeric antigen-presenting gene, a genomic incorporation virus, retrovirus, or lentivirus is commonly used.\textsuperscript{26} Genetic engineering, by use of a retrovirus or lentivirus, has several benefits. Retroviruses and
CAR T Cell Therapy for Cancer and Beyond

Genlecleucel (trade name Kymriah®) received approval in 2017.33 Kymriah is approved for CD19 positive B cell malignancy. Tisagenlecleucel (trade name Yescarta®) is another CAR T cell therapy approved by the FDA in October 2017.33 Kymriah is approved for CD19 positive acute lymphoblastic leukemia and relapsed diffuse large B cell lymphoma. As per the recommendations, it is indicated in patients up to 25 years of age with refractory or second/later relapse large B cell precursor acute lymphoblastic leukemia.31,32

CAR T cells achieve 50% primary remission.38 However, CAR T cell infusion provokes massive inflammation and results in a surge of cytokine production; the most common adverse reaction being cytokine release syndrome. Fortunately, a monoclonal antibody, tocilizumab (trade name Actemra®) is approved to control cytokine release syndrome after CAR T cell infusion.17

Neurological toxicity is also commonly observed, but its specific mechanism remains unclear.36 It is considered to occur independent of the cytokine release syndrome. Mild symptoms such as delirium, expressive aphasia, and obnubilation, as well as severe adverse effects such as death from cerebral edema, have been reported.37 Although most of the neurological adverse reactions are temporary and reversible, CAR T cell infusion should be closely monitored for adverse reactions.

CAR T CELLS IN CANCER TREATMENT

To date, therapeutic outcomes with CAR T cells have mostly been acquired in non-Hodgkin’s lymphoma, because approved CAR T cell treatments target CD19+ B cells. CAR T cell therapy achieved about 70% primary remission and more than 50% of patients acquired complete remission.38 The most promising potential of CAR T cell therapy is that it expands therapeutic options for refractory patients undergoing conventional treatment. Diffuse large B cell lymphoma (DLBCL) is the most common subtype of B cell-related lymphoma and rituximab, an anti-CD20 monoclonal antibody-based chemotherapy, is a well-established strategy. Approximately 50% of DLBCL patients experience complete remission with conventional chemotherapy, but unfortunately, approximately 30% of patients with complete remission by chemotherapy also experience relapse. Furthermore, 20% of DLBCL cases experience primary refractory after chemotherapy.39 CAR T cell achieved 50% complete remission with minimal side effects among patients with primary refractory or relapsed DLBCL by rituximab-based chemotherapy.40

THERAPEUTIC POTENTIALS BEYOND CANCER AND FUTURE PERSPECTIVES

CAR T cell therapy was originally designed to target surface antigens of cancer cell membranes and thereby erase cancer cells; this gives rise to a fundamental question of whether a CAR T cell had the capacity to remove an undesirable non-cancer cell. Recently, Aghajanian et al.41 reported the therapeutic potential of CAR T cells against cells other than cancer cells. First, they generated mice that artificially overexpressed ovalbumin peptide (OVA) in fibroblasts under tamoxifen treatment. Xenogeneic ovalbumin peptide production was controlled under a postin-promoter that was specifically upregulated in activated fibroblasts and not quiescent fibroblasts. The mice were subjected to a continuous infusion of angiotensin II and phenylephrine for 4 weeks, which robustly aggravated myocardial damage and caused subsequent cardiac fibrosis. Next, the mice...
were infused with OVA peptide cognate CD8+ T cells (OT-I CD8+ cells) 1 week after treatment with fibrogenic agonists. Allogeneic transplantation of OT-1 CD8+ cells dramatically ablated the interstitial fibrosis generated by angiotensin II and phenylephrine without significant adverse effects. Based on heat map analysis, fibroblast activation protein (FAP) was determined as the endogenous target for treating fibrosis. Finally, the capability of CAR T cells to target FAP was measured. As in the trial of OT-1 CD8+ cells, FAP CAR T cells were adopted 1 week after cardiac damage and boost transplantation was performed a week later. Massive cardiac fibrosis, measured by Sirius Red staining, was dramatically reversed in the FAP CAR T cell-treated mice. Cardiac dysfunction correlated with interstitial fibrosis had also improved in the FAP CAR T cell mice with evidence of minimal inflammation in various organs.41

CAR T cell approaches can be used to neutralize autoimmune diseases. In autoimmune conditions, antibodies target host cells.42 Memory B cells carrying autoantibodies attack the host. With respect to cell therapy, abnormally activated B cells are the main target for clearance. CAR T cells were originally designed to express antibody-like domains to claim a “cancer antigen”. However, for the CAR T cells to incapacitate an autoimmune disease, they should present antigens recognized by autoimmune B cells. Ellebrecht et al.43 reported the therapeutic potential of CAR T cells in autoimmune dermatitis, Pemphigus vulgaris (PV). Whole B cell ablation by conventional CAR T cells, which targeted CD19+ B cells, resulted not only in an immunocompromised period but also showed notable rates of recurrence. Hence, they designed CAR T cells to specifically target autoimmune antibody-producing B cells. Experimentally, T cells were modified to express the Dsg3 ‘antigen,’ the main target of keratinocytes in PV. The cells were renamed as chimeric autoantibody receptor (CAAR) T cells. CAAR T cell transplantation into the mouse model of PV induces disease remission with a lower rate of recurrence and a minimal risk of an immunocompromised state.43

The most promising feature of CAR T or CAAR T cell treatment is its expandability (Fig. 2). If the antigen binding motif changes, a different cell is targeted therefore, monoclonal antibody therapy can be applied to CAR T treatment. Monoclonal antibody therapies are also designed to target specific human antigens such as cancer antigens (rituximab),44 surface receptors that require fast growth (cetuximab)45 or signal activation (omalizumab).46 They also bind to extremely specific antigens of host cells, which indicates that monoclonal antibodies and their human antigens are already proven therapeutic targets in those diseases. As briefly mentioned above, CAR T cells require engineered surface chimeric antigens that can bind to the cancer antigen. CAR T cell treatment can be applied to human disease by designing CAR T cells to express different single chain fragments of the antibody.47 For example, FAP is not limited to cardiac fibrosis, but is generally expressed in activated fibroblasts.49 In simple terms, FAP CAR T cells could be applied to fibrosis-associated diseases that cannot be controlled by conventional therapeutic approaches. Perinatal infection of hepatitis B virus mainly contributes to chronic hepatitis and hepatic fibrosis, which eventually accelerates hepatic cellular carcinoma.49 In fact, hepatic fibrosis, also known as liver cirrhosis, develops as a result of a normal immune reaction. Virus-infected hepatocytes are subjected to a cell-mediated immune reaction. Unfortunately, the immune reactive death of the infected hepatocytes is rarely effective in clearing the virus, because the released hepatitis virus infects the neighboring hepatocytes. A healthy immune system paradoxically activates a vicious chronic inflammation reaction, which triggers fibrotic changes. Physicians are still only focused on handling the hepatitis virus. However, the complications of liver cirrhosis include portal vein hypertension, peripheral edema, varicose bleeding, and jaundice.50 CAR T cells

**Fig. 2.** Future applications of chimeric antigen receptor T cell therapy or chimeric autoantibody receptor T cell treatment. Solid arrows indicate indications under clinical trial or preclinical trials. Dotted arrows depict expandable human disease by CAR T or CAAR T therapy, respectively. HCC: hepatocellular carcinoma, IPF: idiopathic pulmonary fibrosis, PKD: polycystic kidney disease, SLE: systemic lupus erythematosus.
could be considered a future modality to improve cirrhosis in these types of cases.

Idiopathic pulmonary fibrosis (IPF) is a representative life-threatening fibrosis-associated disease. Although the specific underlying mechanism remains unclear, viral infection or exposure to hazardous gases such as air pollutants or cigarette smoke, are indicated as possible causes. Chronic progressive inflammation finally destroys the pulmonary parenchyma, which is essential for gas exchange; subsequently, the damaged cells are filled with extracellular matrix in the process of fibrosis. The current therapeutic strategy for IPF also focuses on the modulation of inflammation, but it does not reverse fibrosis issues. With consideration of the outcomes in cardiac fibrosis, CAR T cells could be considered to ameliorate the fibrosis issue in IPF.

The indications of CAAR T cells can also be expanded to various autoimmune diseases, such as myasthenia gravis, Hashimoto’s thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, psoriasis, and type 1 diabetes mellitus. Most autoimmune diseases are controlled using immune modulators such as nonsteroidal anti-inflammatory drugs, glucocorticoids, or even mild cytotoxic chemicals to nonspecifically erase immune cells. Based on the CAAR T cell potential for PV, many autoimmune diseases could be included in the future indications of CAAR T cell treatment. Unlike CAR T cells, CAAR T cells express an ‘antigen’ molecule, which means CAAR T cells can activate the humoral immune reaction. Large amounts of antigen, which are attached to a CAAR T cell surface to recognize pre-existing memory B cells, might result in an immense immune reaction. De novo antibody formation can also be considered. Fortunately, no adverse response of the CAAR T cell therapy has been reported to date. Physicians should closely monitor for potential adverse effects when employing CAAR T cell treatment in the future.

CONCLUSION AND LIMITATIONS

A CAR T or CAAR T cell is a T cell obtained from the patient and engineered to serve as personalized medicine. CAR T cells cannot be a ready-to-use regimen. In terms of the commercial aspect, this kind of tailored therapy could pose a massive financial burden on the patient. A CAR T cell also requires an extremely limited, but specific object to target. Hence, CAR T cell therapy shares some clinical features of monoclonal antibody therapy. However, monoclonal therapy can be commercialized more easily. Thus, the cost-effectiveness aspect of CAR T cell treatment is a critical hurdle in the development of the clinical indications of CAR T cell treatment.

For CAR T cell therapy, a specific target is mandatory. However, in many cancers, the cells do not present a unique antigen. Genetic variety of the human genome results in the possibility of different antigens being similar, implying that CAR T cell therapy for cancer antigen requires fine modulation depending on the patient’s polymorphisms. This modulation might worsen clinical applications in the future.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Rosso JD, Zeichner J, Alexis A, Cohen D, Berson D. Understanding the epidermal barrier in healthy and compromised skin: clinically relevant information for the dermatology practitioner: proceedings of an expert panel roundtable meeting. J Clin Aesthet Dermatol 2016;9(4 Suppl 1):S2-8.
2. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001;14:753-77, table of contents.
3. Parkin J, Cohen B. An overview of the immune system. Lancet 2001;357:1777-89.
4. Andersen MH, Schrama D, Thor Straten P, Becker JC. Cytotoxic T cells. J Invest Dermatol 2006;126:32-41.
5. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619.
6. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24:541-50.
7. Greenman C, Stephens P, Smith R, Dalglish GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
8. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsen E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-527.
9. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013;73:3913-26.
10. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015;21:687-92.
11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
12. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008;14:550-9.
13. Chou FC, Chen HY, Kuo CC, Sytwu HK. Role of galectins in tumors and in clinical immunotherapy. Int J Mol Sci 2018;19:E430.
14. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 2017;17:559-72.
15. Dennis KL, Blatner NR, Gounari F, Khazaie K. Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol 2013;25:637-45.
16. Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 2017;31:311-25.
17. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127:3321-30.

18. Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 2015;263:68-89.

19. Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 2018;15:31-46.

20. Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 2018;19:5-18.

21. Singh S, Kumar NK, Dwivedi P, Charan J, Kaur R, Sidhu P, et al. Monoclonal antibodies: a review. Curr Clin Pharmacol 2018;13:85-99.

22. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34.

23. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33.

24. Charrot S, Hallam S. CAR-T cells: future perspectives. Hemasphere 2019;3:e188.

25. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 2016;3:1601.

26. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res 2017;5:22.

27. Hindmarsh P, Leis J. Retroviral DNA integration. Microbiol Mol Biol Rev 1999;63:836-43, table of contents.

28. Maus MV, Haas AR, Beatty GL, Levine BL, Liu X, et al. CD19-targeted chimeric antigen receptors for the treatment of B-cell lymphoblastic leukemia. Hum Immunol 2018;79:E189.

29. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the delivery of transgenes within hematopoietic stem cells. Mol Ther 2018;26:8070-89.

30. Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy. Curr Pharm Biotechnol 2018;19:5-18.

31. Kochenderfer JN, Rosenberg SA. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013;1:26-31.

32. Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy. Curr Pharm Biotechnol 2018;19:5-18.

33. Lee DW, Santomasso BD, Locke FL, Ghojadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625-38.

34. Maude SL, Pinkston MH, Ritz J, Jakobson CA, et al. Targeting cardiac fibrosis with engineered T cells. Science 2019;573:430-3.

35. Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007;67:2585-607.

36. Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 2017;34:2232-73.

37. Lee DW, Santomasso BD, Locke FL, Ghojadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625-38.

38. Maude SL, Pinkston MH, Ritz J, Jakobson CA, et al. Targeting cardiac fibrosis with engineered T cells. Science 2019;573:430-3.

39. Maude SL, Pinkston MH, Ritz J, Jakobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531-44.

40. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the delivery of transgenes within hematopoietic stem cells. Mol Ther 2018;26:8070-89.

41. Salles G, Barrett M, Foa R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 2017;34:2232-73.